Letters Return of the postcode lottery

Opportunity cost of the Cancer Drugs Fund

BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d622 (Published 01 February 2011) Cite this as: BMJ 2011;342:d622
  1. Jonathan Howell, consultant in public health1
  1. 1West Midlands Specialised Commissioning Team, Birmingham B16 9LD, UK
  1. jon.howell{at}wmsc.nhs.uk

Anyone involved with the Interim Cancer Drugs Fund (ICDF) will recognise the inconsistencies and contradictions in trying to make it work for drugs with poor clinical effectiveness.1 As an adviser to the regional ICDF clinical panel, I watch oncologists struggle with the poor quality clinical evidence on the proposed drugs. Many …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe